Nucleic acid ligand complexes

Details Nucleic acid ligand complexes Nucleic acid ligand complexes

1997-10-28

2000-11-14

Zitomer, Stephanie

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 254, 436 6, 436 912, 424 173, 424450, C07H 2102, C07H 2104, C12Q 168, C12P 1934

Patent

active

061472042

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

This invention relates to a method for preparing a therapeutic or diagnostic Complex comprised of a Nucleic Acid Ligand and a Lipophilic Compound or Non-Immunogenic, High Molecular Weight Compound by identifying a Nucleic Acid Ligand by SELEX methodology and associating the Nucleic Acid Ligand with a Lipophilic Compound or a Non-Immunogenic, High Molecular Weight Compound. The invention further relates to improving the pharmacokinetic properties of a Nucleic Acid Ligand by associating the Nucleic Acid Ligand to a Lipophilic Compound or Non-Immunogenic, High Molecular Weight Compound to form a Complex. The invention further relates to a method for targeting a therapeutic or diagnostic agent to a specific predetermined biological Target by associating the agent with a Complex comprised of a Nucleic Acid Ligand and a Lipophilic Compound or Non-Immunogenic, High Molecular Weight Compound, wherein the Nucleic Acid Ligand has a SELEX Target associated with the specific predetermined Target and the Nucleic Acid Ligand is associated with the exterior of the Complex. The invention also includes complexes comprising one or more Nucleic Acid Ligand in association with a Lipophilic Compound or Non-Immunogenic, High Molecular Weight Compound.


BACKGROUND OF THE INVENTION

A. SELEX
The dogma for many years was that nucleic acids had primarily an informational role. Through a method known as Systematic Evolution of Ligands by EXponential enrichment, termed SELEX, it has become clear that nucleic acids have three dimensional structural diversity not unlike proteins. SELEX is a method for the in vitro evolution of nucleic acid molecules with highly specific binding to target molecules and is described in U.S. patent application Ser. No. 07/536,428, filed Jun. 11, 1990, entitled "Systematic Evolution of Ligands by Exponential Enrichment", now abandoned, U.S. patent application Ser. No. 07/714,131, filed Jun. 10, 1991, entitled "Nucleic Acid Ligands", now U.S. Pat. No. 5,475,096, U.S. patent application Ser. No. 07/931,473, filed Aug. 17, 1992, entitled "Methods for Identifying Nucleic Acid Ligands", now U.S. Pat. No. 5,270,163 (see also WO 91/19813), each of which is specifically incorporated by reference herein. Each of these applications, collectively referred to herein as the SELEX Patent Applications, describes a fundamentally novel method for making a Nucleic Acid Ligand to any desired target molecule. The SELEX process provides a class of products which are referred to as Nucleic Acid Ligands, each ligand having a unique sequence, and which has the property of binding specifically to a desired target compound or molecule. Each SELEX-identified Nucleic Acid Ligand is a specific ligand of a given target compound or molecule. SELEX is based on the unique insight that Nucleic Acids have sufficient capacity for forming a variety of two- and three-dimensional structures and sufficient chemical versatility available within their monomers to act as ligands (form specific binding pairs) with virtually any chemical compound, whether monomeric or polymeric. Molecules of any size or composition can serve as targets.
The SELEX method involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of Nucleic Acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound Nucleic Acids from those Nucleic Acids which have bound specifically to target molecules, dissociating the Nucleic Acid-target complexes, amplifying the Nucleic Acids dissociated from the Nucleic Acid-target complexes to yield a ligand-enriched mixture of Nucleic Acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield highly

REFERENCES:
patent: 4861597 (1989-08-01), Kida
patent: 4904582 (1990-02-01), Tullis
patent: 4914210 (1990-04-01), Levenson et al.
patent: 4962029 (1990-10-01), Levenson et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5475096 (1995-12-01), Gold et al.
patent: 5595877 (1997-01-01), Gold et al.
patent: 5614503 (1997-03-01), Chaudhary et al.
Jaschke et al. (1994) Nucleic Acids Res. 22:4810-4817.
MacKellar et al. (1992) Nucleic Acids res. 20:3411-3417.
Shea et al. (1990) Nucleic Acids Res. 18:3777-3783.

Affiliated with

Also associated with

Rating

Nucleic acid ligand complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acid ligand complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid ligand complexes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2066559